Atara Biotherapeutics, Inc. - Common Stock (ATRA)

FDA halts Atara's EBVALLO and ATA3219 trials over manufacturing issues. Atara eyes $60 million milestone from Pierre Fabre upon EBVALLO approval.

CEO Cokey Nguyen expressed confidence in resolving the issue, expecting resubmission and potential approval within six months of addressing the manufacturing compliance concerns.

Atara Biotherapeutics shares are trading higher by 20% Wednesday morning. The company announced a $36 million registered direct offering.

ATRA stock results show that Atara Biotherapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

ATRA stock results show that Atara Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

ATRA stock results show that Atara Biotherapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.